secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001193125-23-142119
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma Q3 net loss $15.4M; cash $112M; Kyowa Kirin ends zandelisib; merger with Infinity pending
--------------------------------------------------------------------------------

- Net loss $15.4M ($2.32/share) in Q3 FY2023 vs $8.7M loss ($1.31/share) in Q3 FY2022.
- Revenue fell to $5.9M from $9.7M due to zandelisib program discontinuation and reduced Kyowa Kirin reimbursements.
- Kyowa Kirin ended zandelisib development in Japan; parties will terminate global license agreement.
- Executed 1-for-20 reverse stock split in April 2023; regained Nasdaq minimum bid compliance as of May 2, 2023.
- Pending all-stock merger with Infinity Pharmaceuticals; combined cash ~$100M expected to fund operations through mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523142119/0001193125-23-142119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523142119/d509683d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-142119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer